Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial

Journal of the National Cancer Institute

Volumn 86, Issue 7, 1994, Pages 539-543

  Meyskens, Frank L ^a   Surwit, Earl ^a   Moon, Thomas E ^a   Childers, Joel M ^a   Davis, John R ^a   Dorr, Robert T ^a   Johnson, Cynthia S ^a   Alberts, David S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID;

ADULT; ARTICLE; CANCER REGRESSION; CELL DIFFERENTIATION; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VAGINA DISCHARGE; VITAMIN BLOOD LEVEL; VULVITIS;

ADMINISTRATION, INTRAVAGINAL; ADULT; ANTINEOPLASTIC AGENTS; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; LOGISTIC MODELS; REMISSION INDUCTION; TRETINOIN; UTERINE CERVICAL NEOPLASMS;

EID: 0028343678     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/86.7.539     Document Type: Article

References (24)

1. Lotan R: Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 605:33-91, 1980.
2. Lippman SM, Kessler JF, Meyskens FL Jr.: Retinoids as preventive and therapeutic anticancer agents (Part I). Cancer Treat Rep 71:391-405, 1987.
3. Meyskens FL Jr.: Clinical trials of retinoids as differentiation inducers. In The Status of Differentiation Therapy in Cancer (Waxman S, Rossi GB, Takaku F, eds). New York: Raven Press, 1987, pp 349-359.
4. Omenn GS, Goodman G, Grizzle J, et al: Recruitment for the β-carotene and retinol efficacy trial (CARET) to prevent lung cancer in smokers and in asbestos-exposed workers. West J Med 156:540-544, 1992.
5. Schneider A, Shah K: The role of vitamins in the etiology of cervical neoplasia: an epidemiological review. Arch Gynecol Obstet 246:1-13, 1989.
6. Surwit EA, Graham V, Droegemueller W, et al: Evaluation of topically applied transretinoic acid in the treatment of cervical intraepithelial lesions. Am J Obstet Gynecol 143:821-823, 1982.
7. Dorr RT, Surwit EA, Meyskens FL Jr., et al: In vitro retinoid binding and release from a collagen sponge material in a simulated intravaginal environment. J Biomed Mater Res 16:839-850, 1982.
8. Meyskens FL Jr, Graham V, Chvapil M, et al: A phase I trial of beta-all-rrans-retinoic acid for mild or moderate intraepithelial cervical neoplasia delivered via a collagen sponge and cervical cap. J Natl Cancer Inst 71:921-925, 1983.
9. Weiner SA, Surwit EA, Graham VE, et al: A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy. Invest New Drugs 4:241-244, 1986.
10. Graham V, Surwit ES, Weiner S, et al: Phase II trial of beta-all-iram-retinoic acid for cervical intraepithelial neoplasia delivered via a collagen sponge and cervical cap. West J Med 145:192-195,1986.
11. Chvapil M: Collagen sponge: theory and practice of medical indications. J Biomed Mater Res 11:721-726, 1977.
12. Poulson HE, Taylor CW: Histological typing of female genital tract tumours. In International Histological Classification of Tumours, vol 13. Geneva: WHO, 1975.
13. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotrentinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801,1980.
14. Agarwal C, Rorke EA, Irwin JC, et al: Immortalization by human papillomavirus type 16 alters retinoid regulation of human ectocervical epithelial cell differentiation. Cancer Res 51:3982-3989,1991.
15. Darwiche N, Celli G, Sly L, et al: Retinoid status controls the appearance of reserve cells and keratin expression in mouse cervical epithelium. Cancer Res 53:2287-2299,1993.
16. Pastorino U, Infante M, Maioli M, et al: Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11:1216-1222, 1993.
17. Garewal HS, Meyskens F Jr.: Retinoids and carotenoids in the prevention of oral cancer: a critical appraisal. Cancer Epidemiol Biomarkers Prev 1:155-159, 1992.
18. Hong WK, Endicott J, Itri LM, et al: 13-e/s-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986.
19. Khan MA, Jenkins GR, Tolleson WH, et al: Retinoic acid inhibition of human papillomavirus type 16-mediated transformation of human keratinocytes. Cancer Res 53:905-909, 1993.
20. Batova A, Danielpour D, Pirisi L, et al: Retinoic acid induces secretion of latent transforming growth factor Pi and P2 in normal and human papillomavirus type 16-immortalized human keratinocytes. Cell Growth Differ 3:763-772, 1992.
21. Petkovich M, Brand NJ, Krust A, et al: A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330:444-450,1987.
22. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al: 13-m-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241-245, 1992.
23. Singh VN, Gaby SK: Premalignant lesions: role of antioxidant vitamins and P-carotene in risk reduction and prevention of malignant transformation. Am J Clin Nutr 53(1 suppl):386-390, 1991.
24. Chiesa F, Tradati N, Marazza M, et al: Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Eur J Cancer 28:97-102, 1992.